ArticleBritish journal of cancer2025

A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Kenneth Sooi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.